Vistagen therapeutics stock.

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report), with a price target of $12.00. Jason McCarthy’s Buy ...Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment …Sep 21, 2023 · Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ... In addition, VistaGen Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ...

Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...

VistaGen Therapeutics (VTGN) stock price prediction is 4.1154543085612 USD. The VistaGen Therapeutics stock forecast is 4.1154543085612 USD for 2024 ...

SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ...Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol (PH94B) nasal …VistaGen Therapeutics (NASDAQ: VTGN) is a name you should know when it comes to cheap stocks. The company focuses on developing next-generation therapies for central nervous system (CNS) disorders and other therapeutic areas. While most penny stocks are speculative and risky, VistaGen has several specialties that make it worth …Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m. (Simply Wall St.) Sep-20-22 08:30AM. Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit.

Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade …

VistaGen Therapeutics (VTGN) stock price prediction is 4.1154543085612 USD. The VistaGen Therapeutics stock forecast is 4.1154543085612 USD for 2024 ...

Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued. Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ... Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After hours: 07:55PM...View 13F filing holders of VistaGen Therapeutics Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.Mar 22, 2023 · VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ...

Vistagen to conduct small U.S. Phase 1 trial with newly optimized formulation of PH10 in Q1 2023 to confirm favorable safety profile from three previous clinical trials and to facilitate Phase 2B development of PH10 for major depressive disorder. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 30, 2022-- Vistagen, (NASDAQ: …Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into ... The Company explicitly disclaims any obligation to update any forward-looking statements. VistaGen Company Contacts. Mark McPartland / Mark Flather. VistaGen Therapeutics. Phone: (650) 577-3606 ...By Colin Kellaher. Vistagen Therapeutics shares tumbled on Monday after the clinical-stage biopharmaceutical company said it was raising $100 million in a public offering of stock and warrants.According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.Fasedienol, itruvone, and VistaGen’s other pherines (PH80, PH15, and PH284) address major markets across mental health crisis to women’s health. Price Action: VTGN shares are up 13.42% at $4. ...3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ...

Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After hours: 07:55PM...See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...

In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.Oct 6, 2023 · Vistagen Therapeutics Inc ( VTGN) is up 6.73% today. VTGN has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.12 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ... PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014.The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023.The analyst firm set a price target for $30.00 expecting VTGN to rise to within ...MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8.Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ...

VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.

On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.

Aug 14, 2023 · Vistagen to Present at Stifel 2023 Healthcare Conference Nov 08, 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders ... The average price target represents a 123.64% change from the last price of $3.13.Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. VistaGen Therapeutics, Inc. Daily – Vickers Top Buyers & Sellers for 11/16/2023 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the …Summary of all time highs, changes and price drops for Vistagen Therapeutics; Historical stock prices; Current Share Price: US$3.65: 52 Week High: …In addition, VistaGen Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ...VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. ... Arcturus Therapeutics (ARCT), another stock ...Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol. Stock Price Forecast The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00.Vistagen therapeutics added 17% on tuesday after stifel initiated its coverage with a buy recommendation for the company's anxiety disorder drug, fasedienol. ... Webull offers Vistagen Therapeutics Inc stock information, including NASDAQ: VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate ...Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ...

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for ...VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ...Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. Instagram:https://instagram. health insurance companies in marylandwhat is atandt dividendnasdaq menyf etf Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ... what does leverage mean in forextesla german stock See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. is toggle auto insurance good Find the latest Vistagen Therapeutics, Inc. (VTGN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Advertisement Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After...Maxim Group analyst Jason McCarthy maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report) yesterday and set a price target of $30.00.The company’s shares closed today at $6. ...